Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.

ABSTRACT:

Background

The recent innovation activities of global top-tier pharmaceutical companies in accordance with global and regional health concerns were investigated in order to identify their innovations contributing to population health.

Methods

"Innovation activity" was defined as the number of drugs for which R&D activities have been reported within the last three years. Such activities were measured by collecting the data on drug developments and classifying them by developer company, phase of development, therapeutic use, and the country in which the development conducted. Subsequently, we examined and compared the correlations between the global innovation activities of the top 20 pharmaceutical companies and the disease burden measured in disability-adjusted life years (D

SUBMITTER: Jung YL 

PROVIDER: S-EPMC7481343 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature